Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 12:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Osteoarthritis of the Hip or Knee Clear all
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002

NCT02336698
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Phoenix, Arizona • Costa Mesa, California • Laguna Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 1 Interventional

To Assess the Patients' Ability to Self-Administer Fasinumab

NCT03491904
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab AI, Fasinumab PFS
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
Gilbert, Arizona • Glendale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain

NCT01510912
View directory record Official record
Conditions
Osteoarthritis
Interventions
Diclofenac
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 3 Interventional

Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007

NCT02301234
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg, Celecoxib 100 mg, Celecoxib 100 mg Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
32
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Hip or Knee (2)

NCT00863304
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, naproxen, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee

NCT00313846
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years to 75 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
44
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 8, 2026, 12:59 PM EDT
Terminated Phase 3 Interventional Results available

Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

NCT00960804
View directory record Official record
Conditions
Osteoarthritis
Interventions
Tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Atlantis, Florida • Fort Myers, Florida • South Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

NCT02697773
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Placebo, Tanezumab 2.5 mg, Tanezumab 2.5mg/5mg
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Surprise, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 8, 2026, 12:59 PM EDT
Active, not recruiting Not applicable Interventional

Conversations in Health Literacy Using AI Technology for Osteoarthritis Patients

NCT06778486
View directory record Official record
Conditions
Osteoarthritis, Osteoarthritis of the Hip or Knee
Interventions
Artificial Intelligence Chatbot
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Study of Diclofenac Capsules to Treat Osteoarthritis Pain

NCT01461369
View directory record Official record
Conditions
Osteoarthritis
Interventions
Diclofenac, Placebo
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Not applicable Interventional Results available

Shoe Lifts for Leg Length Inequality in Adults With Knee or Hip Symptoms

NCT01894100
View directory record Official record
Conditions
Leg Length Inequality, Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Shoe lift correction for leg length inequality
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
55 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Smithfield, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 8, 2026, 12:59 PM EDT
Terminated Phase 3 Interventional Results available

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

NCT03285646
View directory record Official record
Conditions
Chronic Low Back Pain, Osteoarthritis
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
56
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

NCT02683239
View directory record Official record
Conditions
Osteoarthritis of the Knee or Hip
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
50
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 2 Interventional

A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee

NCT02524197
View directory record Official record
Conditions
Osteoarthritis
Interventions
CR845 0.25 mg, CR845 0.50 mg, CR845 1 mg, CR845 5 mg
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
25 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Omaha, Nebraska • Las Vegas, Nevada • Greensboro, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 8, 2026, 12:59 PM EDT
Completed No phase listed Observational

An Analysis of the Outcomes From Protocolized Perioperative Care for Patients Receiving Total Hip or Knee Arthroplasty

NCT03071250
View directory record Official record
Conditions
Knee Osteoarthritis, Hip Osteoarthritis, Knee Arthritis, Hip Arthritis
Interventions
Total knee or Hip Arthroplasty
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee

NCT02944448
View directory record Official record
Conditions
Osteoarthritis, Hip, Osteoarthritis, Knee, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions
CR845 tablet 1 mg, CR845 tablet 2.5 mg, CR845 tablet 5 mg, Placebo tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
25 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

NCT03691974
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 2Phase 3 Interventional

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

NCT02447276
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
REGN475, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

NCT03304379
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions
Fasinumab, Diclofenac, Celecoxib, Matching placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
71
States / cities
Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 8, 2026, 12:59 PM EDT
Terminated Phase 3 Interventional Results available

Tanezumab In Osteoarthritis Of The Hip Or Knee

NCT00985621
View directory record Official record
Conditions
Osteoarthritis
Interventions
tanezumab 10 mg, tanezumab 5 mg, oxycodone, placebo
Biological · Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 8, 2026, 12:59 PM EDT
Completed Not applicable Interventional

Study of Antibiotic Spacer Design to Treat Infection After Hip Replacement

NCT01373099
View directory record Official record
Conditions
Osteoarthritis, Hip Infection, Prosthetic Joint Infection, Complications; Arthroplasty, Infection or Inflammation, Complications; Arthroplasty
Interventions
Implantation of a static, non-articulating cement spacer., Implantation of an articulating spacer.
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 8, 2026, 12:59 PM EDT